Nalaganje...
Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas
BACKGROUND: Iniparib is a prodrug that converts to highly reactive cytotoxic metabolites intracellularly with activity in preclinical glioma models. We investigated the maximum tolerated dose (MTD) of iniparib with monthly (m) and continuous (c) temozolomide (TMZ) dosing schedules in patients with m...
Shranjeno v:
| izdano v: | J Neurooncol |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2015
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4869687/ https://ncbi.nlm.nih.gov/pubmed/26285766 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-015-1876-0 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|